Apellis Pharmaceuticals Key Executives
This section highlights Apellis Pharmaceuticals's key executives, including their titles and compensation details.
Find Contacts at Apellis Pharmaceuticals
(Showing 0 of )
Apellis Pharmaceuticals Earnings
This section highlights Apellis Pharmaceuticals's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-28 | $-0.37 | $-0.29 |
| Read Transcript | Q3 | 2024 | 2024-11-05 | $-0.32 | $-0.46 |
| Read Transcript | Q2 | 2024 | 2024-08-01 | $-0.33 | $-0.28 |
| Read Transcript | Q1 | 2024 | 2024-05-07 | $-0.54 | $-0.54 |
| Read Transcript | Q4 | 2023 | 2024-02-27 | $-0.66 | $-0.73 |
| Read Transcript | Q3 | 2023 | 2023-11-01 | $-0.84 | $-1.17 |
| Read Transcript | Q2 | 2023 | 2023-07-31 | $-1.35 | $-1.02 |
| Read Transcript | Q1 | 2023 | 2023-05-06 | N/A | N/A |
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
$22.68
Stock Price
$2.85B
Market Cap
705
Employees
Waltham, MA
Location
Financial Statements
Access annual & quarterly financial statements for Apellis Pharmaceuticals, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $709.95M | $396.59M | $75.42M | $66.56M | $250.65M |
| Cost of Revenue | $117.72M | $58.51M | $5.64M | $5.20M | $25.05M |
| Gross Profit | $592.23M | $338.08M | $69.79M | $61.36M | $225.60M |
| Gross Profit Ratio | 83.42% | 85.20% | 92.53% | 92.20% | 90.01% |
| Research and Development Expenses | $327.57M | $354.39M | $387.24M | $420.87M | $299.92M |
| General and Administrative Expenses | $- | $500.81M | $277.16M | $176.77M | $139.40M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $501.05M | $500.81M | $277.16M | $176.77M | $139.40M |
| Other Expenses | $- | $- | $-288.00K | $1.36M | $-501.00K |
| Operating Expenses | $828.62M | $855.20M | $664.40M | $597.64M | $439.32M |
| Cost and Expenses | $946.35M | $913.71M | $670.03M | $602.84M | $464.37M |
| Interest Income | $12.77M | $20.93M | $8.91M | $418.00K | $4.16M |
| Interest Expense | $40.39M | $29.58M | $32.63M | $13.24M | $29.94M |
| Depreciation and Amortization | $1.80M | $1.70M | $1.49M | $1.49M | $859.00K |
| EBITDA | $-236.39M | $-495.21M | $-617.39M | $-731.27M | $-312.23M |
| EBITDA Ratio | -33.30% | -124.87% | -774.97% | -800.75% | -83.55% |
| Operating Income | $-236.39M | $-517.12M | $-594.61M | $-536.28M | $-213.73M |
| Operating Income Ratio | -33.30% | -130.39% | -788.38% | -805.67% | -85.27% |
| Total Other Income Expenses Net | $39.68M | $-9.38M | $-56.89M | $-209.72M | $-129.30M |
| Income Before Tax | $-196.72M | $-526.50M | $-651.50M | $-746.00M | $-343.03M |
| Income Before Tax Ratio | -27.71% | -132.76% | -863.81% | -1120.75% | -136.86% |
| Income Tax Expense | $1.16M | $2.13M | $669.00K | $352.00K | $1.84M |
| Net Income | $-197.88M | $-528.63M | $-652.17M | $-746.35M | $-344.87M |
| Net Income Ratio | -27.87% | -133.29% | -864.70% | -1121.27% | -137.59% |
| EPS | $-1.60 | $-4.45 | $-6.15 | $-8.84 | $-4.59 |
| EPS Diluted | $-1.60 | $-4.45 | $-6.15 | $-8.84 | $-4.59 |
| Weighted Average Shares Outstanding | 123.90M | 118.68M | 106.11M | 84.42M | 75.16M |
| Weighted Average Shares Outstanding Diluted | 123.90M | 118.68M | 106.11M | 84.42M | 75.16M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $212.53M | $196.83M | $199.69M | $172.32M | $146.38M | $99.18M | $94.97M | $44.85M | $22.66M | $22.06M | $16.32M | $14.38M | $60.29M | $5.65M | $623.00K | $- | $250.00M | $646.00K | $- | $- |
| Cost of Revenue | $40.86M | $33.56M | $23.55M | $20.65M | $19.91M | $22.41M | $8.38M | $7.81M | $2.92M | $1.38M | $82.00K | $1.25M | $5.05M | $149.00K | $50.00M | $124.59M | $54.01M | $93.21M | $115.51M | $98.79M |
| Gross Profit | $171.67M | $163.27M | $176.14M | $151.67M | $126.47M | $76.77M | $86.59M | $37.04M | $19.74M | $20.68M | $16.24M | $13.13M | $55.24M | $5.50M | $-49.38M | $-124.59M | $195.99M | $-92.56M | $-115.51M | $-98.79M |
| Gross Profit Ratio | 80.78% | 83.00% | 88.20% | 88.00% | 86.40% | 77.40% | 91.20% | 82.60% | 87.10% | 93.70% | 99.50% | 91.30% | 91.60% | 97.40% | -7925.70% | 0.00% | 78.40% | -14328.33% | 0.00% | 0.00% |
| Research and Development Expenses | $76.35M | $88.57M | $77.95M | $84.70M | $69.28M | $79.42M | $95.66M | $110.03M | $99.42M | $95.21M | $101.66M | $90.94M | $103.18M | $87.73M | $145.94M | $84.01M | $50.34M | $93.21M | $87.09M | $69.28M |
| General and Administrative Expenses | $- | $- | $- | $- | $141.70M | $145.65M | $111.37M | $102.09M | $84.37M | $78.41M | $63.20M | $51.19M | $41.46M | $45.76M | $48.97M | $40.58M | $44.49M | $36.99M | $28.41M | $29.50M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $121.48M | $121.98M | $127.63M | $129.06M | $141.70M | $145.65M | $111.37M | $102.09M | $84.37M | $78.41M | $63.20M | $51.19M | $41.46M | $45.76M | $48.97M | $40.58M | $44.49M | $36.99M | $28.41M | $29.50M |
| Other Expenses | $- | $- | $24.00K | $-499.00K | $219.00K | $-603.00K | $-63.00K | $-277.00K | $-246.00K | $99.00K | $149.00K | $-289.00K | $-4.00K | $-117.00K | $-61.00K | $1.54M | $-505.00K | $-16.00K | $5.00K | $14.00K |
| Operating Expenses | $197.84M | $210.55M | $205.58M | $213.76M | $210.98M | $225.07M | $207.03M | $212.12M | $183.79M | $173.61M | $164.86M | $142.13M | $144.64M | $133.50M | $194.91M | $124.59M | $94.83M | $130.20M | $115.51M | $98.79M |
| Cost and Expenses | $238.69M | $244.11M | $229.13M | $234.41M | $230.90M | $247.48M | $215.41M | $219.93M | $186.72M | $174.99M | $164.95M | $143.38M | $149.69M | $133.65M | $194.91M | $124.59M | $119.88M | $130.20M | $115.51M | $98.79M |
| Interest Income | $3.40M | $2.89M | $3.18M | $3.30M | $4.55M | $4.99M | $6.00M | $5.39M | $4.58M | $2.81M | $1.43M | $98.00K | $37.00K | $144.00K | $104.00K | $134.00K | $194.00K | $670.00K | $1.02M | $2.27M |
| Interest Expense | $11.53M | $12.53M | $9.36M | $6.97M | $7.40M | $7.31M | $7.34M | $7.53M | $7.74M | $7.90M | $8.45M | $8.54M | $3.02M | $2.28M | $3.77M | $4.17M | $9.61M | $9.50M | $6.91M | $3.92M |
| Depreciation and Amortization | $454.00K | $621.00K | $449.00K | $444.00K | $490.00K | $405.00K | $410.00K | $399.00K | $428.00K | $357.00K | $342.00K | $360.00K | $376.00K | $274.00K | $448.00K | $394.00K | $58.00K | $315.00K | $122.00K | $142.00K |
| EBITDA | $-24.08M | $-43.86M | $-27.73M | $-58.84M | $-79.26M | $-132.29M | $-114.09M | $-169.57M | $-159.30M | $-182.56M | $-146.70M | $-128.83M | $-144.34M | $-193.01M | $-214.98M | $-179.09M | $90.00M | $-125.89M | $-111.59M | $-164.76M |
| EBITDA Ratio | -11.33% | -22.29% | -14.52% | -35.77% | -57.41% | -149.52% | -120.57% | -378.11% | -702.89% | -678.60% | -898.79% | -895.83% | -147.61% | -2260.07% | -31106.90% | 0.00% | 51.95% | -19904.49% | 0.00% | 0.00% |
| Operating Income | $-26.16M | $-47.28M | $-29.44M | $-62.09M | $-84.52M | $-148.30M | $-120.44M | $-175.08M | $-164.05M | $-152.94M | $-148.62M | $-129.00M | $-89.40M | $-128.00M | $-194.29M | $-124.59M | $130.12M | $-129.55M | $-115.51M | $-98.79M |
| Operating Income Ratio | -12.31% | -24.02% | -14.74% | -36.03% | -57.74% | -149.52% | -126.82% | -390.41% | -723.88% | -693.41% | -910.57% | -897.00% | -148.29% | -2265.40% | -31185.71% | 0.00% | 52.05% | -20054.49% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $-9.90M | $-9.57M | $-8.10M | $-4.16M | $-2.63M | $-2.92M | $-1.40M | $-2.41M | $-3.41M | $-37.88M | $-6.87M | $-8.73M | $-58.18M | $-67.58M | $-24.90M | $-59.07M | $-50.01M | $-6.15M | $-3.11M | $-70.04M |
| Income Before Tax | $-36.07M | $-56.85M | $-37.54M | $-66.25M | $-87.15M | $-140.00M | $-121.84M | $-177.50M | $-167.46M | $-190.82M | $-155.49M | $-137.73M | $-147.58M | $-195.57M | $-219.19M | $-183.66M | $80.11M | $-135.70M | $-118.62M | $-168.82M |
| Income Before Tax Ratio | -16.97% | -28.88% | -18.80% | -38.45% | -59.54% | -141.16% | -128.30% | -395.79% | -738.92% | -865.18% | -952.65% | -957.70% | -244.79% | -3461.43% | -35183.15% | 0.00% | 32.04% | -21006.19% | 0.00% | 0.00% |
| Income Tax Expense | $286.00K | $592.00K | $114.00K | $170.00K | $1.42M | $233.00K | $194.00K | $282.00K | $-1.47M | $446.00K | $486.00K | $1.21M | $352.00K | $2.17M | $3.71M | $5.72M | $1.84K | $9.48M | $6.91M | $3.93M |
| Net Income | $-36.35M | $-57.45M | $-37.66M | $-66.42M | $-88.58M | $-140.24M | $-122.04M | $-177.78M | $-165.99M | $-191.27M | $-155.98M | $-138.94M | $-147.93M | $-195.57M | $-219.19M | $-183.66M | $78.27M | $-135.70M | $-118.62M | $-168.82M |
| Net Income Ratio | -17.11% | -29.19% | -18.86% | -38.55% | -60.51% | -141.39% | -128.50% | -396.42% | -732.43% | -867.20% | -955.62% | -966.10% | -245.37% | -3461.43% | -35183.15% | 0.00% | 31.31% | -21006.19% | 0.00% | 0.00% |
| EPS | $-0.29 | $-0.46 | $-0.30 | $-0.54 | $-0.73 | $-1.17 | $-1.02 | $-1.56 | $-1.50 | $-1.75 | $-1.46 | $-1.42 | $-1.73 | $-2.28 | $-2.72 | $-2.32 | $0.99 | $-1.79 | $-1.57 | $-2.29 |
| EPS Diluted | $-0.29 | $-0.46 | $-0.30 | $-0.54 | $-0.73 | $-1.17 | $-1.02 | $-1.56 | $-1.50 | $-1.75 | $-1.46 | $-1.42 | $-1.73 | $-2.28 | $-2.72 | $-2.32 | $0.99 | $-1.79 | $-1.57 | $-2.29 |
| Weighted Average Shares Outstanding | 123.90M | 123.90M | 123.90M | 122.96M | 121.23M | 120.29M | 119.32M | 113.87M | 110.63M | 109.13M | 106.63M | 97.84M | 85.66M | 85.66M | 80.65M | 79.22M | 75.88M | 75.63M | 75.55M | 73.72M |
| Weighted Average Shares Outstanding Diluted | 123.90M | 123.90M | 123.90M | 122.96M | 121.23M | 120.29M | 119.32M | 113.87M | 110.63M | 109.13M | 106.63M | 98.07M | 85.66M | 85.66M | 80.65M | 79.22M | 79.22M | 75.63M | 75.55M | 73.72M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $411.29M | $351.19M | $551.80M | $640.19M | $565.78M |
| Short Term Investments | $- | $1.11M | $6.50M | $60.36M | $311.87M |
| Cash and Short Term Investments | $411.29M | $352.30M | $551.80M | $700.55M | $877.65M |
| Net Receivables | $264.93M | $206.44M | $7.73M | $10.10M | $25.00M |
| Inventory | $81.40M | $146.36M | $85.71M | $16.29M | $1 |
| Other Current Assets | $31.33M | $61.23M | $73.01M | $97.11M | $14.54M |
| Total Current Assets | $788.95M | $766.33M | $719.52M | $824.05M | $917.19M |
| Property Plant Equipment Net | $19.04M | $21.09M | $24.89M | $26.08M | $24.52M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $3.24M | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $77.06M | $-1.93M | $15.80M | $31.64M | $18.86M |
| Total Non-Current Assets | $96.10M | $22.40M | $40.69M | $57.72M | $43.38M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $885.05M | $788.73M | $760.22M | $881.76M | $960.57M |
| Account Payables | $38.57M | $37.52M | $37.34M | $16.91M | $8.48M |
| Short Term Debt | $13.51M | $6.44M | $5.62M | $4.12M | $3.69M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $103.24M | $111.94M |
| Other Current Liabilities | $133.43M | $203.64M | $124.64M | $110.82M | $116.17M |
| Total Current Liabilities | $185.51M | $247.59M | $167.61M | $131.85M | $128.33M |
| Long Term Debt | $463.03M | $104.49M | $107.09M | $206.10M | $374.05M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $7.97M | $242.13M | $315.65M | $345.15M | $253.64M |
| Total Non-Current Liabilities | $471.00M | $346.62M | $422.74M | $551.26M | $627.68M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $656.51M | $594.21M | $590.35M | $683.10M | $756.01M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $12.00K | $12.00K | $11.00K | $10.00K | $8.00K |
| Retained Earnings | $-3.04B | $-2.84B | $-2.31B | $-1.66B | $-926.35M |
| Accumulated Other Comprehensive Income Loss | $-3.31M | $-3.54M | $-875.00K | $-2.09M | $-117.00K |
| Other Total Stockholders Equity | $3.27B | $3.04B | $2.48B | $1.86B | $1.13B |
| Total Stockholders Equity | $228.54M | $194.52M | $169.87M | $198.66M | $204.56M |
| Total Equity | $228.54M | $194.52M | $169.87M | $198.66M | $204.56M |
| Total Liabilities and Stockholders Equity | $885.05M | $788.73M | $760.22M | $881.76M | $960.57M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $885.05M | $788.73M | $760.22M | $881.76M | $960.57M |
| Total Investments | $- | $4.35M | $6.50M | $60.36M | $311.87M |
| Total Debt | $469.78M | $110.93M | $112.71M | $210.22M | $377.73M |
| Net Debt | $58.49M | $-240.26M | $-439.09M | $-429.97M | $-188.05M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $411.29M | $396.86M | $361.43M | $327.03M | $352.30M | $452.41M | $616.26M | $765.08M | $551.80M | $584.19M | $604.49M | $633.46M | $640.19M | $283.75M | $270.76M | $265.44M | $565.78M | $415.56M | $317.35M | $417.88M |
| Short Term Investments | $- | $- | $7.95M | $7.62M | $4.35M | $13.12M | $9.42M | $9.04M | $6.50M | $124.36M | $248.31M | $331.84M | $60.36M | $146.57M | $328.25M | $458.24M | $311.87M | $312.60M | $515.48M | $228.81M |
| Cash and Short Term Investments | $411.29M | $396.86M | $361.43M | $327.03M | $352.30M | $452.41M | $616.26M | $765.08M | $551.80M | $708.55M | $852.80M | $965.30M | $700.55M | $430.31M | $599.01M | $723.67M | $877.65M | $728.16M | $832.82M | $646.69M |
| Net Receivables | $271.72M | $283.97M | $308.85M | $267.84M | $206.44M | $186.99M | $128.30M | $31.50M | $7.73M | $8.09M | $7.52M | $6.33M | $10.10M | $3.52M | $719.00K | $20.00M | $25.00M | $- | $- | $- |
| Inventory | $81.40M | $121.06M | $152.77M | $161.28M | $146.36M | $98.55M | $103.22M | $85.48M | $85.71M | $59.75M | $48.45M | $32.85M | $16.29M | $1.68M | $3.73M | $1 | $1 | $- | $- | $- |
| Other Current Assets | $24.54M | $32.01M | $36.92M | $55.28M | $61.23M | $58.82M | $44.91M | $72.18M | $73.01M | $55.54M | $51.20M | $99.50M | $97.11M | $39.92M | $51.67M | $29.95M | $14.54M | $14.19M | $21.00M | $25.71M |
| Total Current Assets | $788.95M | $833.90M | $859.97M | $811.43M | $766.33M | $796.77M | $892.69M | $954.25M | $719.52M | $831.94M | $959.97M | $1.10B | $824.05M | $475.43M | $655.13M | $773.62M | $917.19M | $742.35M | $853.83M | $672.41M |
| Property Plant Equipment Net | $19.04M | $20.44M | $20.16M | $19.19M | $21.09M | $20.27M | $22.07M | $23.82M | $24.89M | $25.20M | $26.65M | $25.86M | $26.08M | $27.44M | $28.69M | $29.59M | $24.52M | $25.08M | $15.38M | $15.69M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $77.06M | $47.53M | $24.35M | $1.31M | $1.31M | $1.18M | $827.00K | $793.00K | $15.80M | $15.75M | $15.88M | $16.01M | $31.64M | $22.82M | $16.10M | $6.91M | $18.86M | $909.00K | $906.00K | $845.00K |
| Total Non-Current Assets | $96.10M | $67.97M | $44.51M | $20.50M | $22.40M | $21.45M | $22.89M | $24.61M | $40.69M | $40.95M | $42.53M | $41.87M | $57.72M | $50.26M | $44.79M | $36.50M | $43.38M | $25.98M | $16.28M | $16.53M |
| Other Assets | $- | $- | $1 | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $885.05M | $901.87M | $904.48M | $831.93M | $788.73M | $818.22M | $915.58M | $978.87M | $760.22M | $872.89M | $1.00B | $1.15B | $881.76M | $525.69M | $699.91M | $810.13M | $960.57M | $768.33M | $870.11M | $688.94M |
| Account Payables | $38.57M | $42.73M | $38.27M | $26.79M | $37.52M | $18.19M | $27.50M | $31.49M | $37.34M | $14.10M | $16.22M | $12.27M | $16.91M | $4.98M | $5.34M | $4.16M | $8.48M | $11.07M | $9.93M | $3.08M |
| Short Term Debt | $6.75M | $13.58M | $12.43M | $6.26M | $6.44M | $5.74M | $5.85M | $5.83M | $5.62M | $5.42M | $5.31M | $4.56M | $4.12M | $4.07M | $4.04M | $3.90M | $3.69M | $3.44M | $2.66M | $2.73M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $1.90M | $1.90M | $3.56M | $- | $117.09M | $97.72M | $- | $- | $- | $- | $- | $103.24M | $69.85M | $134.30M | $69.40M | $111.94M | $- | $- | $- |
| Other Current Liabilities | $140.18M | $133.04M | $116.57M | $178.69M | $203.64M | $161.70M | $141.49M | $101.32M | $124.64M | $95.92M | $105.26M | $107.94M | $110.82M | $85.18M | $148.41M | $75.61M | $116.17M | $60.77M | $45.40M | $44.93M |
| Total Current Liabilities | $185.51M | $191.26M | $169.17M | $215.29M | $247.59M | $185.63M | $174.84M | $138.64M | $167.61M | $115.45M | $126.79M | $124.77M | $131.85M | $94.24M | $157.79M | $83.67M | $128.33M | $75.27M | $57.99M | $50.74M |
| Long Term Debt | $463.03M | $463.66M | $468.30M | $347.31M | $104.49M | $103.84M | $104.95M | $106.04M | $107.09M | $107.95M | $205.99M | $205.86M | $206.10M | $207.76M | $405.60M | $406.06M | $374.05M | $369.44M | $359.58M | $155.96M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $7.97M | $9.83M | $2.69M | $2.66M | $242.13M | $296.48M | $290.39M | $322.06M | $315.65M | $342.08M | $335.30M | $352.99M | $345.15M | $281.02M | $278.02M | $268.74M | $253.64M | $217.78M | $220.47M | $223.25M |
| Total Non-Current Liabilities | $471.00M | $473.49M | $470.99M | $349.96M | $346.62M | $400.31M | $395.34M | $428.10M | $422.74M | $450.03M | $541.29M | $558.85M | $551.26M | $488.78M | $683.62M | $674.80M | $627.68M | $587.22M | $580.05M | $379.20M |
| Other Liabilities | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $656.51M | $664.75M | $640.15M | $565.25M | $594.21M | $585.95M | $570.17M | $566.75M | $590.35M | $565.48M | $668.08M | $683.62M | $683.10M | $583.01M | $841.40M | $758.47M | $756.01M | $662.49M | $638.04M | $429.94M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $12.00K | $12.00K | $12.00K | $12.00K | $12.00K | $12.00K | $12.00K | $12.00K | $11.00K | $11.00K | $11.00K | $11.00K | $10.00K | $9.00K | $8.00K | $8.00K | $8.00K | $8.00K | $8.00K | $7.00K |
| Retained Earnings | $-3.04B | $-3.00B | $-2.94B | $-2.90B | $-2.84B | $-2.75B | $-2.61B | $-2.49B | $-2.31B | $-2.14B | $-1.95B | $-1.80B | $-1.66B | $-1.51B | $-1.31B | $-1.09B | $-926.35M | $-1.00B | $-868.91M | $-750.29M |
| Accumulated Other Comprehensive Income Loss | $-3.31M | $-3.14M | $-3.36M | $-3.52M | $-3.54M | $-1.06M | $-796.00K | $-775.00K | $-875.00K | $-3.03M | $-3.19M | $-2.06M | $-2.09M | $-2.01M | $-1.83M | $-1.62M | $-117.00K | $-1.76M | $329.00K | $1.01M |
| Other Total Stockholders Equity | $3.27B | $3.24B | $3.21B | $3.17B | $3.04B | $2.98B | $2.95B | $2.90B | $2.48B | $2.45B | $2.29B | $2.26B | $1.86B | $1.45B | $1.17B | $1.15B | $1.13B | $1.11B | $1.10B | $1.01B |
| Total Stockholders Equity | $228.54M | $237.12M | $264.33M | $266.68M | $194.52M | $232.27M | $345.40M | $412.12M | $169.87M | $307.42M | $334.42M | $462.24M | $198.66M | $-57.33M | $-141.49M | $51.66M | $204.56M | $105.84M | $232.06M | $259.00M |
| Total Equity | $228.54M | $237.12M | $264.33M | $266.68M | $194.52M | $232.27M | $345.40M | $412.12M | $169.87M | $307.42M | $334.42M | $462.24M | $198.66M | $-57.33M | $-141.49M | $51.66M | $204.56M | $105.84M | $232.06M | $259.00M |
| Total Liabilities and Stockholders Equity | $885.05M | $901.87M | $904.48M | $831.93M | $788.73M | $818.22M | $915.58M | $978.87M | $760.22M | $872.89M | $1.00B | $1.15B | $881.76M | $525.69M | $699.91M | $810.13M | $960.57M | $768.33M | $870.11M | $688.94M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $885.05M | $901.87M | $904.48M | $831.93M | $788.73M | $818.22M | $915.58M | $978.87M | $760.22M | $872.89M | $1.00B | $1.15B | $881.76M | $525.69M | $699.91M | $810.13M | $960.57M | $768.33M | $870.11M | $688.94M |
| Total Investments | $- | $- | $7.95M | $7.62M | $4.35M | $13.12M | $9.42M | $9.04M | $6.50M | $124.36M | $248.31M | $331.84M | $60.36M | $146.57M | $328.25M | $458.24M | $311.87M | $312.60M | $515.48M | $228.81M |
| Total Debt | $469.78M | $470.45M | $474.51M | $430.85M | $110.93M | $109.58M | $110.80M | $111.87M | $112.71M | $113.37M | $211.30M | $210.42M | $210.22M | $211.83M | $409.63M | $409.96M | $377.73M | $372.88M | $362.24M | $158.69M |
| Net Debt | $58.49M | $73.58M | $113.08M | $103.82M | $-241.37M | $-342.84M | $-505.46M | $-653.21M | $-439.09M | $-470.82M | $-393.19M | $-423.04M | $-429.97M | $-71.91M | $138.87M | $144.53M | $-188.05M | $-42.68M | $44.89M | $-259.19M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-197.88M | $-528.63M | $-652.17M | $-746.35M | $-344.87M |
| Depreciation and Amortization | $1.80M | $1.70M | $1.49M | $1.49M | $637.00K |
| Deferred Income Tax | $- | $- | $- | $198.26M | $103.03M |
| Stock Based Compensation | $114.13M | $105.94M | $91.08M | $70.67M | $45.38M |
| Change in Working Capital | $- | $-200.17M | $-15.70M | $-93.52M | $19.59M |
| Accounts Receivables | $-58.48M | $- | $2.38M | $-10.10M | $- |
| Inventory | $-10.76M | $- | $-69.40M | $-16.32M | $- |
| Accounts Payables | $1.09M | $170.00K | $18.69M | $10.49M | $-54.00K |
| Other Working Capital | $- | $-200.34M | $32.63M | $-77.59M | $19.64M |
| Other Non Cash Items | $-5.91M | $26.41M | $61.55M | $6.33M | $15.76M |
| Net Cash Provided by Operating Activities | $-87.87M | $-594.74M | $-513.75M | $-563.13M | $-160.49M |
| Investments in Property Plant and Equipment | $-403.00K | $-773.00K | $-1.52M | $-1.10M | $-5.42M |
| Acquisitions Net | $- | $- | $-61.42M | $-248.72M | $311.57M |
| Purchases of Investments | $- | $- | $-331.86M | $-171.28M | $-879.07M |
| Sales Maturities of Investments | $- | $- | $393.28M | $420.00M | $567.50M |
| Other Investing Activities | $- | $99.00K | $61.42M | $248.72M | $-311.57M |
| Net Cash Used for Investing Activities | $-403.00K | $-674.00K | $59.89M | $247.62M | $-316.99M |
| Debt Repayment | $365.45M | $- | $- | $- | $322.87M |
| Common Stock Issued | $- | $384.39M | $380.12M | $380.36M | $381.42M |
| Common Stock Repurchased | $4.51M | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-216.21M | $10.11M | $-14.46M | $11.87M | $369.30M |
| Net Cash Used Provided by Financing Activities | $149.24M | $394.50M | $365.66M | $392.24M | $692.18M |
| Effect of Forex Changes on Cash | $-659.00K | $135.00K | $-488.00K | $-2.02M | $359.00K |
| Net Change in Cash | $60.31M | $-200.78M | $-88.68M | $74.71M | $215.06M |
| Cash at End of Period | $412.61M | $352.30M | $553.07M | $641.75M | $567.04M |
| Cash at Beginning of Period | $352.30M | $553.07M | $641.75M | $567.04M | $351.99M |
| Operating Cash Flow | $-87.87M | $-594.74M | $-513.75M | $-563.13M | $-160.49M |
| Capital Expenditure | $-403.00K | $-773.00K | $-1.52M | $-1.10M | $-5.42M |
| Free Cash Flow | $-88.27M | $-595.51M | $-515.27M | $-564.23M | $-165.91M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-36.35M | $-57.45M | $-37.66M | $-66.42M | $-88.58M | $-140.24M | $-122.04M | $-177.78M | $-165.99M | $-191.27M | $-155.98M | $-138.94M | $-147.93M | $-195.57M | $-219.19M | $-183.66M | $78.27M | $-135.70M | $-118.62M | $-168.82M |
| Depreciation and Amortization | $454.00K | $457.00K | $449.00K | $444.00K | $490.00K | $405.00K | $410.00K | $399.00K | $428.00K | $357.00K | $342.00K | $360.00K | $376.00K | $274.00K | $448.00K | $394.00K | $58.00K | $315.00K | $122.00K | $142.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-133.00K | $133.00K | $- | $- | $- | $- | $- | $- | $55.19M | $65.32M | $21.18M | $56.57M | $40.09M | $-2.70M | $-2.77M | $68.41M |
| Stock Based Compensation | $26.31M | $27.48M | $29.99M | $30.35M | $26.22M | $21.62M | $29.28M | $28.82M | $24.24M | $23.54M | $22.53M | $20.77M | $19.31M | $17.19M | $17.72M | $16.44M | $12.49M | $12.10M | $11.49M | $9.29M |
| Change in Working Capital | $28.36M | $62.79M | $-6.18M | $-103.50M | $-42.56M | $-57.50M | $-64.33M | $-35.79M | $-4.42M | $-28.40M | $18.95M | $-1.82M | $-40.78M | $-58.49M | $50.83M | $-45.09M | $5.79M | $21.23M | $11.93M | $-19.36M |
| Accounts Receivables | $14.09M | $25.42M | $-36.58M | $-61.41M | $-37.17M | $-58.36M | $-79.41M | $-23.78M | $365.00K | $-574.00K | $-1.19M | $3.77M | $-7.49M | $-1.90M | $-719.00K | $- | $719.00K | $- | $- | $- |
| Inventory | $10.02M | $8.65M | $-14.51M | $-14.92M | $-47.82M | $4.67M | $-17.65M | $144.00K | $-25.96M | $-11.30M | $-15.60M | $-16.53M | $-14.64M | $2.05M | $-3.73M | $- | $3.73M | $- | $- | $- |
| Accounts Payables | $1.49M | $-1.16M | $11.49M | $-10.73M | $19.62M | $-9.60M | $-4.00M | $-5.85M | $23.13M | $-7.03M | $8.96M | $-6.37M | $13.70M | $83.00K | $874.00K | $-4.17M | $-2.45M | $792.00K | $6.84M | $-5.24M |
| Other Working Capital | $2.76M | $29.87M | $33.42M | $-16.43M | $22.81M | $5.79M | $36.72M | $29.49M | $-1.95M | $-9.50M | $26.78M | $17.31M | $-32.36M | $-58.73M | $49.96M | $-40.92M | $3.79M | $20.44M | $5.09M | $-14.13M |
| Other Non Cash Items | $587.00K | $822.00K | $75.54M | $124.44M | $6.68M | $6.49M | $6.52M | $6.72M | $5.00M | $41.36M | $7.13M | $8.06M | $1.33M | $2.65M | $319.00K | $2.03M | $5.28M | $4.93M | $3.55M | $1.99M |
| Net Cash Provided by Operating Activities | $19.36M | $34.10M | $-8.34M | $-132.98M | $-97.88M | $-169.09M | $-150.16M | $-177.62M | $-140.74M | $-154.42M | $-107.02M | $-111.56M | $-112.50M | $-168.62M | $-128.69M | $-153.31M | $141.98M | $-99.82M | $-94.29M | $-108.35M |
| Investments in Property Plant and Equipment | $-20.00K | $- | $-90.00K | $-293.00K | $-95.00K | $-47.00K | $-372.00K | $-259.00K | $-851.00K | $-196.00K | $-391.00K | $-86.00K | $-19.00K | $-352.00K | $-248.00K | $-484.00K | $-711.00K | $-3.74M | $-538.00K | $-435.00K |
| Acquisitions Net | $- | $- | $- | $- | $99.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $52.50M | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $331.86M | $- | $-331.86M | $-331.86M | $-1.00K | $1.00K | $- | $-171.28M | $-311.88M | $1.00K | $-339.77M | $-227.42M |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $124.98M | $124.98M | $83.32M | $60.00M | $85.00M | $180.00M | $130.00M | $25.00M | $312.50M | $202.50M | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $99.00K | $- | $- | $- | $-331.86M | $124.98M | $331.86M | $-271.86M | $85.00M | $180.00M | $130.00M | $-146.28M | $-52.50M | $202.50M | $52.50M | $-227.42M |
| Net Cash Used for Investing Activities | $-20.00K | $- | $-90.00K | $-293.00K | $4.00K | $-47.00K | $-372.00K | $-259.00K | $124.13M | $124.78M | $82.93M | $-271.95M | $84.98M | $179.65M | $129.75M | $-146.76M | $-91.00K | $198.76M | $-287.81M | $-227.85M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-200.00K | $323.07M | $- |
| Common Stock Issued | $- | $-14.63M | $-98.76M | $98.76M | $27.09M | $5.76M | $26.09M | $384.39M | $-380.12M | $10.64M | $380.12M | $380.12M | $380.36M | $2.48M | $8.76M | $2.59M | $-381.42M | $381.42M | $-170.00K | $381.59M |
| Common Stock Repurchased | $- | $3.22M | $- | $- | $-2.00K | $-11.00K | $-28.00K | $- | $4.24M | $-1.00M | $-536.00K | $- | $- | $-361.00K | $-234.00K | $-956.00K | $1.57M | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $-1.56M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-4.00M | $2.54M | $42.49M | $9.45M | $-2.35M | $5.75M | $1.56M | $6.72M | $-14.22M | $9.64M | $-12.04M | $-3.42M | $3.60M | $2.12M | $4.53M | $1.63M | $6.32M | $1.13M | $-41.41M | $21.67M |
| Net Cash Used Provided by Financing Activities | $-4.00M | $2.54M | $42.49M | $108.21M | $-3.91M | $5.75M | $1.56M | $391.11M | $-15.95M | $9.64M | $-4.74M | $376.70M | $383.96M | $2.12M | $4.53M | $1.63M | $6.32M | $926.00K | $281.67M | $403.27M |
| Effect of Forex Changes on Cash | $-965.00K | $173.00K | $342.00K | $-209.00K | $584.00K | $-458.00K | $-47.00K | $56.00K | $187.00K | $-310.00K | $-429.00K | $64.00K | $8.00K | $-172.00K | $-241.00K | $-1.61M | $2.02M | $-1.65M | $132.00K | $-152.00K |
| Net Change in Cash | $14.38M | $36.81M | $34.40M | $-25.27M | $-101.20M | $-163.84M | $-149.01M | $213.28M | $-32.37M | $-20.31M | $-29.26M | $-6.74M | $356.45M | $12.97M | $5.35M | $-300.06M | $150.23M | $98.22M | $-100.30M | $66.91M |
| Cash at End of Period | $412.61M | $398.24M | $361.43M | $327.03M | $352.30M | $453.50M | $617.34M | $766.36M | $553.07M | $585.45M | $605.75M | $635.01M | $641.75M | $285.31M | $272.34M | $266.99M | $567.04M | $416.81M | $318.60M | $418.90M |
| Cash at Beginning of Period | $398.24M | $361.43M | $327.03M | $352.30M | $453.50M | $617.34M | $766.36M | $553.08M | $585.45M | $605.75M | $635.01M | $641.75M | $285.31M | $272.34M | $266.99M | $567.04M | $416.81M | $318.60M | $418.90M | $351.99M |
| Operating Cash Flow | $19.36M | $34.10M | $-8.34M | $-132.98M | $-97.88M | $-169.09M | $-150.16M | $-177.62M | $-140.74M | $-154.42M | $-107.02M | $-111.56M | $-112.50M | $-168.62M | $-128.69M | $-153.31M | $141.98M | $-99.82M | $-94.29M | $-108.35M |
| Capital Expenditure | $-20.00K | $- | $-90.00K | $-293.00K | $-95.00K | $-47.00K | $-372.00K | $-259.00K | $-851.00K | $-196.00K | $-391.00K | $-86.00K | $-19.00K | $-352.00K | $-248.00K | $-484.00K | $-711.00K | $-3.74M | $-538.00K | $-435.00K |
| Free Cash Flow | $19.34M | $34.10M | $-8.43M | $-133.28M | $-97.97M | $-169.13M | $-150.53M | $-177.88M | $-141.59M | $-154.61M | $-107.42M | $-111.65M | $-112.52M | $-168.98M | $-128.94M | $-153.80M | $141.27M | $-103.56M | $-94.83M | $-108.78M |
Apellis Pharmaceuticals Dividends
Explore Apellis Pharmaceuticals's dividend history, including dividend yield, payout ratio, and historical payments.
Apellis Pharmaceuticals News
Read the latest news about Apellis Pharmaceuticals, including recent articles, headlines, and updates.
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
The U.S. Food and Drug Administration (FDA) on Tuesday accepted and granted Priority Review designation to Apellis Pharmaceuticals, Inc.'s APLS supplemental New Drug Application (sNDA) for Empaveli (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
PDUFA target action date is July 28, 2025 WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation of the supplemental New Drug Application (sNDA) for EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are severe and rare kidney diseases.
Apellis Pharmaceuticals: A Mixed Bag
Commerical stage Apellis Pharmaceuticals, Inc. recently reported Q4 results that beat expectations. The company posted impressive revenue growth and cost reduction in FY2024. It is a bit of a complicated tale around this mid-cap, but the company looks set to move to profitability with the funding it has on hand.
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst
Last week, Apellis Pharmaceuticals Inc APLS reported a fourth-quarter earnings loss of 29 cents per share, beating the consensus loss of 37 cents. Sales increased 45.2% to $212.5 million, beating the consensus of $198.35 million.
Apellis Pharmaceuticals, Inc. (APLS) Q4 2024 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ET Company Participants Cedric Francois - Co-Founder and CEO Caroline Baumal - Chief Medical Officer David Acheson - EVP, Commercial Tim Sullivan - CFO Meredith Kaya - SVP, IR and Strategic Finance Conference Call Participants Jon Miller - Evercore ISI Tazeen Ahmad - Bank of America Securities Malcolm Kuno - J.P. Morgan Salveen Richter - Goldman Sachs Yigal Nochomovitz - Citigroup Colleen Cusi - Robert W.
Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Apellis Pharmaceuticals (APLS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET.
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
WALTHAM, Mass. and STOCKHOLM, Sweden, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are rare, chronic kidney diseases with no approved treatments.
Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
WALTHAM, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, at 8:30 a.m.
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the company approved the grant of equity awards to three new employees with a grant date of February 3, 2025, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)
WALTHAM, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan) for the every-other-month treatment of adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) with an intact fovea and when central vision is threatened by GA lesion growth. SYFOVRE is the first and only approved treatment for GA in Australia.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Shareholders to Connect
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Apellis Pharmaceuticals, Inc. (APLS) And Encourages Shareholders to Reach Out
NEW YORK, NY / ACCESS Newswire / January 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Shareholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / January 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Investors to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Investors to Connect
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Bronstein, Gewirtz & Grossman, LLC Encourages Apellis Pharmaceuticals, Inc. (APLS) Stockholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced preliminary U.S. net product revenues for the fourth quarter and the full year 2024 for SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration and for EMPAVELI® (pegcetacoplan) for adults with paroxysmal nocturnal hemoglobinuria (PNH) as well as its strategic priorities for continued growth.
APLS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Apellis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
NEW YORK, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Stockholders to Connect
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / January 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Stockholders to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / January 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Bronstein, Gewirtz & Grossman, LLC Encourages Apellis Pharmaceuticals, Inc. (APLS) Investors to Inquire about Securities Investigation
NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for APLS.